{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:51:23Z","timestamp":1793379083663,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T00:00:00Z","timestamp":1588636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012021","name":"IRAN UNIVERSITY OF MEDICAL SCIENCES","doi-asserted-by":"crossref","award":["1396.9321540001"],"award-info":[{"award-number":["1396.9321540001"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV)-associated malignancy remain a main cause of cancer in men and women. Cancer immunotherapy has represented great potential as a new promising cancer therapeutic approach. Here, we report Mesenchymal stem cells (MSCs) as a carrier for the delivery of oncolytic Newcastle disease virus (NDV) for the treatment of HPV-associated tumor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>For this purpose, MSCs obtained from the bone marrow of C57BL mice, then cultured and characterized subsequently by the flow cytometry analysis for the presence of cell surface markers. In this study, we sought out to determine the impacts of MSCs loaded with oncolytic NDV on splenic T cell and cytokine immune responses, caspase-3 and -9 expression, and myeloid and myeloid-derived suppressor cells (MDSCs) by histological and immunohistochemical studies in the tumor microenvironment (TME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings proved that MSCs possess both migratory capacity and tumor tropism toward transplanted tumor tissue after peritumoral administration. Tumor therapy experiments indicated that oncolytic NDV delivered by MSCs-engineered system significantly reduces tumor growth, which is associated with the enhancement of E7-specific lymphocyte proliferation, CD8+ T cell cytolysis responses, and splenic IFN-\u03b3, IL-4 and IL-12 responses compared with control groups. Moreover, the treatment upregulated the concentration of apoptotic proteins (caspase 9) and increased infiltration of tumor microenvironment with CD11b\u2009+\u2009myeloid and Gr1\u2009+\u2009MDSCs cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data suggest MSCs carrying oncolytic NDV as a potentially effective strategy for cancer immunotherapy through inducing splenic Th1 immune responses and apoptosis in the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01326-w","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T15:03:07Z","timestamp":1588690987000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment"],"prefix":"10.1186","volume":"17","author":[{"given":"Mohsen","family":"Keshavarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Saeed","family":"Ebrahimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Miri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Dianat-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Sara","family":"Ghorbanhosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Reza","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ghaemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,5]]},"reference":[{"key":"1326_CR1","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/S0140-6736(03)13778-6","volume":"361","author":"SE Waggoner","year":"2003","unstructured":"Waggoner SE. Cervical cancer. Lancet. 2003;361:2217\u201325.","journal-title":"Lancet"},{"key":"1326_CR2","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4143\/crt.2005.37.6.319","volume":"37","author":"E-K Yim","year":"2005","unstructured":"Yim E-K, Park J-S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res Treat. 2005;37:319.","journal-title":"Cancer Res Treat"},{"key":"1326_CR3","doi-asserted-by":"publisher","first-page":"pky045","DOI":"10.1093\/jncics\/pky045","volume":"2","author":"S de Sanjos\u00e9","year":"2018","unstructured":"de Sanjos\u00e9 S, Serrano B, Tous S, Alejo M, Lloveras B, Quir\u00f3s B, Clavero O, Vidal A, Ferr\u00e1ndiz-Pulido C, Pav\u00f3n MA. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58. JNCI Cancer Spectrum. 2018;2:pky045.","journal-title":"JNCI Cancer Spectrum"},{"key":"1326_CR4","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa021641","volume":"348","author":"N Mu\u00f1oz","year":"2003","unstructured":"Mu\u00f1oz N, Bosch FX, De Sanjos\u00e9 S, Herrero R, Castellsagu\u00e9 X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518\u201327.","journal-title":"N Engl J Med"},{"key":"1326_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1326_CR6","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler SE, Speranza M-C, Cho C-F, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3:841\u20139.","journal-title":"JAMA Oncol"},{"key":"1326_CR7","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nrc948","volume":"2","author":"EA Chiocca","year":"2002","unstructured":"Chiocca EA. Oncolytic viruses. Nat Rev Cancer. 2002;2:938.","journal-title":"Nat Rev Cancer"},{"key":"1326_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12929-019-0542-9","volume":"26","author":"M Keshavarz","year":"2019","unstructured":"Keshavarz M, Solaymani-Mohammadi F, Miri SM, Ghaemi A. Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy. J Biomed Sci. 2019;26:48.","journal-title":"J Biomed Sci"},{"key":"1326_CR9","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/mt.2011.65","volume":"19","author":"A Melcher","year":"2011","unstructured":"Melcher A, Parato K, Rooney CM, Bell JC. Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 2011;19:1008\u201316.","journal-title":"Mol Ther"},{"key":"1326_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/cgt.2008.31","volume":"15","author":"B Yaacov","year":"2008","unstructured":"Yaacov B, Elihaoo E, Ben-Shlomo M, Greenbaum I, Panet A, Zakay-Rones Z. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors. Cancer Gene Ther. 2008;15:795.","journal-title":"Cancer Gene Ther"},{"key":"1326_CR11","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1089\/hum.2011.207","volume":"23","author":"D Wei","year":"2012","unstructured":"Wei D, Sun N, Nan G, Wang Y, Liu H-Q, Peeters B, Chen Z-N, Bian H. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther. 2012;23:700\u201310.","journal-title":"Hum Gene Ther"},{"key":"1326_CR12","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1517\/14712598.2015.1088000","volume":"15","author":"V Schirrmacher","year":"2015","unstructured":"Schirrmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Expert Opin Biol Ther. 2015;15:1757\u201371.","journal-title":"Expert Opin Biol Ther"},{"key":"1326_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/mt.2014.204","volume":"23","author":"J Martinez-Quintanilla","year":"2015","unstructured":"Martinez-Quintanilla J, He D, Wakimoto H, Alemany R, Shah K. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol Ther. 2015;23:108\u201318.","journal-title":"Mol Ther"},{"key":"1326_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biomaterials.2017.09.009","volume":"147","author":"B-K Jung","year":"2017","unstructured":"Jung B-K, Oh E, Hong J, Lee Y, Park KD, Yun C-O. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response. Biomaterials. 2017;147:26\u201338.","journal-title":"Biomaterials"},{"key":"1326_CR15","doi-asserted-by":"publisher","first-page":"45415","DOI":"10.18632\/oncotarget.17557","volume":"8","author":"E Rinc\u00f3n","year":"2017","unstructured":"Rinc\u00f3n E, Cejalvo T, Kanojia D, Alfranca A, Rodr\u00edguez-Milla M\u00c1, Hoyos RAG, Han Y, Zhang L, Alemany R, Lesniak MS. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model. Oncotarget. 2017;8:45415.","journal-title":"Oncotarget"},{"key":"1326_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jcyt.2017.02.002","volume":"19","author":"BCP Kerrigan","year":"2017","unstructured":"Kerrigan BCP, Shimizu Y, Andreeff M, Lang FF. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy. 2017;19:445\u201357.","journal-title":"Cytotherapy"},{"key":"1326_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.virusres.2018.12.014","volume":"261","author":"A Mohebbi","year":"2019","unstructured":"Mohebbi A, Ebrahimzadeh MS, Rahimi SB, Saeidi M, Tabarraei A, Mohebbi SR, Shirian S, Gorji A, Ghaemi A. Non-replicating Newcastle disease virus as an adjuvant for DNA vaccine enhances antitumor efficacy through the induction of TRAIL and granzyme B expression. Virus Res. 2019;261:72\u201380.","journal-title":"Virus Res"},{"key":"1326_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3892\/ijmm.2013.1244","volume":"31","author":"M Ghrici","year":"2013","unstructured":"Ghrici M, El Zowalaty M, Omar AR, Ideris A. Newcastle disease virus Malaysian strain AF2240 induces apoptosis in MCF-7 human breast carcinoma cells at an early stage of the virus life cycle. Int J Mol Med. 2013;31:525\u201332.","journal-title":"Int J Mol Med"},{"key":"1326_CR19","first-page":"45","volume":"13","author":"RJ Walter","year":"2012","unstructured":"Walter RJ, Attar BM, Rafiq A, Tejaswi S, Delimata M. Newcastle disease virus LaSota strain kills human pancreatic cancer cells in vitro with high selectivity. JOP J Pancreas. 2012;13:45\u201353.","journal-title":"JOP J Pancreas"},{"key":"1326_CR20","doi-asserted-by":"publisher","first-page":"40849","DOI":"10.1039\/C7RA07175B","volume":"7","author":"SR Ahmed","year":"2017","unstructured":"Ahmed SR, Nagy \u00c9, Neethirajan S. Self-assembled star-shaped chiroplasmonic gold nanoparticles for an ultrasensitive chiro-immunosensor for viruses. RSC Adv. 2017;7:40849\u201357.","journal-title":"RSC Adv"},{"key":"1326_CR21","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s12035-016-9840-3","volume":"54","author":"M Togha","year":"2017","unstructured":"Togha M, Jahanshahi M, Alizadeh L, Jahromi SR, Vakilzadeh G, Alipour B, Gorji A, Ghaemi A. Rapamycin augments immunomodulatory properties of bone marrow-derived mesenchymal stem cells in experimental autoimmune encephalomyelitis. Mol Neurobiol. 2017;54:2445\u201357.","journal-title":"Mol Neurobiol"},{"key":"1326_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/cgt.2012.35","volume":"19","author":"H Kosaka","year":"2012","unstructured":"Kosaka H, Ichikawa T, Kurozumi K, Kambara H, Inoue S, Maruo T, Nakamura K, Hamada H, Date I. Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. Cancer Gene Ther. 2012;19:572\u20138.","journal-title":"Cancer Gene Ther"},{"key":"1326_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13287-016-0414-0","volume":"7","author":"G Kazimirsky","year":"2016","unstructured":"Kazimirsky G, Jiang W, Slavin S, Ziv-Av A, Brodie C. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther. 2016;7:149.","journal-title":"Stem Cell Res Ther"},{"key":"1326_CR24","first-page":"119","volume":"9","author":"A Ghaemi","year":"2012","unstructured":"Ghaemi A, Soleimanjahi H, Razeghi S, Gorji A, Tabaraei A, Moradi A, Alizadeh A, Vakili MA. Genistein induces a protective immunomodulatory effect in a mouse model of cervical cancer. Iran J Immunol. 2012;9:119\u201327.","journal-title":"Iran J Immunol"},{"key":"1326_CR25","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1007\/s12010-012-9700-1","volume":"167","author":"R Kumar","year":"2012","unstructured":"Kumar R, Tiwari AK, Chaturvedi U, Kumar GR, Sahoo AP, Rajmani R, Saxena L, Saxena S, Tiwari S, Kumar S. Velogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol. 2012;167:2005\u201322.","journal-title":"Appl Biochem Biotechnol"},{"key":"1326_CR26","doi-asserted-by":"crossref","unstructured":"Keshavarz M, Nejad ASM, Esghaei M, Bokharaei-Salim F, Dianat-Moghadam H, Keyvani H, Ghaemi A. Oncolytic Newcastle disease virus reduces growth of cervical cancer cell by inducing apoptosis. Saudi J Biol Sci. 2020;27:47\u201352.","DOI":"10.1016\/j.sjbs.2019.04.015"},{"key":"1326_CR27","doi-asserted-by":"crossref","unstructured":"Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A: Cancer stem cells: the root of tumor recurrence and metastases. Semin Cancer Biol. 2017;44:10\u201324.","DOI":"10.1016\/j.semcancer.2017.02.011"},{"key":"1326_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12943-017-0597-8","volume":"16","author":"SM Ridge","year":"2017","unstructured":"Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16:31.","journal-title":"Mol Cancer"},{"key":"1326_CR29","doi-asserted-by":"publisher","first-page":"873","DOI":"10.17219\/acem\/73720","volume":"27","author":"H Abdelmawgoud","year":"2018","unstructured":"Abdelmawgoud H, Saleh A. Anti-inflammatory and antioxidant effects of mesenchymal and hematopoietic stem cells in a rheumatoid arthritis rat model. Adv Clin Exp Med. 2018;27:873\u201380.","journal-title":"Adv Clin Exp Med"},{"key":"1326_CR30","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658.","journal-title":"Nat Biotechnol"},{"key":"1326_CR31","doi-asserted-by":"publisher","first-page":"E6157","DOI":"10.1073\/pnas.1707139114","volume":"114","author":"W Du","year":"2017","unstructured":"Du W, Seah I, Bougazzoul O, Choi G, Meeth K, Bosenberg MW, Wakimoto H, Fisher D, Shah K. Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. Proc Natl Acad Sci. 2017;114:E6157\u201365.","journal-title":"Proc Natl Acad Sci"},{"key":"1326_CR32","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.1158\/1078-0432.CCR-09-1292","volume":"15","author":"EK Mader","year":"2009","unstructured":"Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB, Peng K-W. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res. 2009;15:7246\u201355.","journal-title":"Clin Cancer Res"},{"key":"1326_CR33","first-page":"1","volume":"4","author":"JG Pol","year":"2012","unstructured":"Pol JG, Ress\u00e9guier J, Lichty BD. Oncolytic viruses: a step into cancer immunotherapy. Virus Adapt Treat. 2012;4:1\u201321.","journal-title":"Virus Adapt Treat"},{"key":"1326_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","volume":"41","author":"J De Graaf","year":"2018","unstructured":"De Graaf J, de Vor L, Fouchier R, Van Den Hoogen B. Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 2018;41:28\u201339.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1326_CR35","first-page":"1514","volume":"8","author":"T Ye","year":"2018","unstructured":"Ye T, Jiang K, Wei L, Barr MP, Xu Q, Zhang G, Ding C, Meng S, Piao H. Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. Am J Cancer Res. 2018;8:1514.","journal-title":"Am J Cancer Res"},{"key":"1326_CR36","doi-asserted-by":"publisher","first-page":"E313","DOI":"10.1002\/ijc.29202","volume":"136","author":"CA Koks","year":"2015","unstructured":"Koks CA, Garg AD, Ehrhardt M, Riva M, Vandenberk L, Boon L, Vleeschouwer SD, Agostinis P, Graf N, Van Gool SW. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer. 2015;136:E313\u201325.","journal-title":"Int J Cancer"},{"key":"1326_CR37","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1331807","volume":"6","author":"Z Wang","year":"2017","unstructured":"Wang Z, Till B, Gao Q. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells. Oncoimmunology. 2017;6:e1331807.","journal-title":"Oncoimmunology"},{"key":"1326_CR38","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1080414","volume":"5","author":"L Fend","year":"2016","unstructured":"Fend L, Remy-Ziller C, Foloppe J, Kempf J, Cochin S, Barraud L, Accart N, Erbs P, Fournel S, Pr\u00e9ville X. Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment. Oncoimmunology. 2016;5:e1080414.","journal-title":"Oncoimmunology"},{"key":"1326_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omto.2017.09.003","volume":"7","author":"EK Ring","year":"2017","unstructured":"Ring EK, Li R, Moore BP, Nan L, Kelly VM, Han X, Beierle EA, Markert JM, Leavenworth JW, Gillespie GY. Newly characterized murine undifferentiated sarcoma models sensitive to virotherapy with oncolytic HSV-1 M002. Molecular Therapy-Oncolytics. 2017;7:27\u201336.","journal-title":"Molecular Therapy-Oncolytics"},{"key":"1326_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02088-w","volume":"9","author":"MC Schmid","year":"2018","unstructured":"Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, Anand S, Woo G, Leem C, Faridi MH. Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun. 2018;9:1\u201314.","journal-title":"Nat Commun"},{"key":"1326_CR41","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1038\/s41467-018-07387-4","volume":"9","author":"MC Schmid","year":"2018","unstructured":"Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, Anand S, Woo G, Leem C, Faridi MH. Integrin CD11b activation drives anti-tumor innate immunity. Nat Commun. 2018;9:5379.","journal-title":"Nat Commun"},{"key":"1326_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1743-422X-11-84","volume":"11","author":"Z Chai","year":"2014","unstructured":"Chai Z, Zhang P, Fu F, Zhang X, Liu Y, Hu L, Li X. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer. Virol J. 2014;11:84.","journal-title":"Virol J"},{"key":"1326_CR43","doi-asserted-by":"crossref","unstructured":"Zendedel E, Atkin SL, Sahebkar A. Use of stem cells as carriers of oncolytic viruses for cancer treatment. J Cell Physiol. 2019.","DOI":"10.1002\/jcp.28320"},{"key":"1326_CR44","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3109\/14653249.2010.542457","volume":"13","author":"C Song","year":"2011","unstructured":"Song C, Li G. CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy. 2011;13:549\u201361.","journal-title":"Cytotherapy"},{"key":"1326_CR45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/sj.mt.6300128","volume":"15","author":"K Hamada","year":"2007","unstructured":"Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A, Tagawa M. Carrier cell\u2013mediated delivery of a replication-competent adenovirus for Cancer gene therapy. Mol Ther. 2007;15:1121\u20138.","journal-title":"Mol Ther"},{"key":"1326_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1158\/1535-7163.MCT-18-0431","volume":"18","author":"R Moreno","year":"2019","unstructured":"Moreno R, Fajardo CA, Farrera-Sal M, Peris\u00e9-Barrios AJ, Morales-Molina A, Al-Zaher AA, Garcia-Castro J, Alemany R. Enhanced antitumor efficacy of Oncolytic adenovirus\u2013loaded menstrual blood\u2013derived Mesenchymal stem cells in combination with peripheral blood mononuclear cells. Mol Cancer Ther. 2019;18:127\u201338.","journal-title":"Mol Cancer Ther"}],"updated-by":[{"DOI":"10.1186\/s12985-020-01444-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000}}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01326-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T04:10:16Z","timestamp":1650514216000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,5]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01326-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.21140\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.21140\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,5]]},"assertion":[{"value":"13 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were performed according to the Ethical Committee for the use and care of laboratory animals of Iran University of Medical Sciences (ethics number: IR.IUMS.FMD.REC 1396.9321540001).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}